definiens: means that the activity referred to would be unreasonable to pursue given theefforts and resources normally used by a pharmaceutical or biotechnology company, as applicable, of comparable size andresources of such Party, in the exercise of its reasonable business discretion relating to such activity with respect to a similarproduct with similar product characteristics, that is of similar market potential at a similar stage in its Development or productlife, taking into account issues of patent coverage, safety and efficacy, product profile, the competitiveness of the marketplace, the proprietary position of the compound or product, the regulatory structure involved, and other technical, legal, scientificand / or medical factors, and, solely with respect to BSP ’s Development and/or Commercialization ( but not Research ) ofCollaboration Compounds under this Agreement, the profitability of such Collaboration Compounds ( including withoutlimitation pricing and reimbursement status achieved ) as compared to other products within BSP ’s portfolio